| Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways (NCT05124288) | Ciceri Fabio | 2022-07-18 |
| Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia (NCT05506332) | University Hospital, Antwerp | 2022-07-15 |
| AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT05211570) | AB Science | 2022-06-01 |
| Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) (NCT05488132) | Xuzhou Medical University | 2022-04-01 |
| Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia (NCT04867928) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2022-03-01 |
| PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML (NCT05105152) | Seattle Children's Hospital | 2021-11-29 |
| Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia (NCT04898894) | St. Jude Children's Research Hospital | 2021-11-15 |
| KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia (NCT04914845) | University of Colorado, Denver | 2021-08-27 |
| CD123 Redirected T Cells for AML in Pediatric Subjects (NCT04678336) | University of Pennsylvania | 2021-04-02 |
| Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT04402541) | Cleave Therapeutics, Inc. | 2020-06-08 |
| Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (NCT03957915) | Institut Paoli-Calmettes | 2020-05-29 |
| Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment (NCT04321161) | University of Freiburg | 2020-02-25 |
| Lentivirally Redirected CD123 Autologous T Cells in AML (NCT03766126) | University of Pennsylvania | 2018-12-06 |
| A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML (NCT03690154) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2018-07-23 |
| A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia (NCT03053206) | All India Institute of Medical Sciences | 2017-02-15 |
| High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML (NCT02768792) | UNC Lineberger Comprehensive Cancer Center | 2016-08-22 |
| PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK) (NCT02438761) | Institut Curie | 2015-08-31 |
| Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia (NCT02353143) | Menarini Group | 2014-12-01 |
| A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02204085) | Beth Israel Deaconess Medical Center | 2014-09-01 |